New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - trabectedin 0.25mg - powder for infusion - 0.25 mg - active: trabectedin 0.25mg excipient: monobasic potassium phosphate phosphoric acid potassium hydroxide sucrose - yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - aminolevulinic acid hydrochloride 1.5 g - powder for oral solution - 1.5 g - active: aminolevulinic acid hydrochloride 1.5 g - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging , and who are intended for resection of the tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - fluocinolone acetonide 190ug - intraocular implant - 190 mcg - active: fluocinolone acetonide 190ug excipient: med-1137 rtv silicone adhesive polyvinyl alcohol   pyromellitic dianhydride, 4,4'-oxydianiline polymer - for the treatment of diabetic macular oedema (dme) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (iop).

New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - ripretinib 50mg - tablet - 50 mg - active: ripretinib 50mg excipient: colloidal silicon dioxide crospovidone hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose - qinlock is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumours (gist) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics glio pty ltd - aminolevulinic acid hydrochloride, quantity: 1.5 g - oral liquid, powder for - excipient ingredients: - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging, and who are intended for resection of the tumour.

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics pharma pty ltd - lurbinectedin, quantity: 4 mg - injection, powder for - excipient ingredients: sucrose; sodium hydroxide; (s)-lactic acid - zepzelca is indicated for the treatment of patients with metastatic small cell lung cancer (sclc) that has progressed on or after prior platinum-containing therapy. this indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single arm trial. continued approval for this indication depends on verification and description of clinical benefit in a confirmatory trial.

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics alim pty ltd - fluocinolone acetonide, quantity: 190 microgram - implant - excipient ingredients: polyvinyl alcohol; pmda/oda copolymer; dimeticonol; ethyltriacetoxysilane; methyltriacetoxysilane; dibutyltin diacetate; silica dimethicone silylate - iluvien is indicated for the treatment of diabetic macular oedema (dme) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (iop).

New Zealand - English - Medsafe (Medicines Safety Authority)

specialised therapeutics limited - neratinib maleate 48.31mg equivalent to neratinib 40 mg - film coated tablet - 40 mg - active: neratinib maleate 48.31mg equivalent to neratinib 40 mg excipient: colloidal silicon dioxide crospovidone opadry ii red 85f15443 magnesium stearate mannitol microcrystalline cellulose povidone purified water - indicated for the extended adjuvant treatment of adult patients with early-stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics australia pty ltd - palonosetron hydrochloride; palonosetron -

Australia - English - Department of Health (Therapeutic Goods Administration)

specialised therapeutics australia pty ltd - fidaxomicin -